The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Hemostasis sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Hemostasis LLC (Hemostasis) is a medical device company that manufactures and designs bleeding control technology products. The company’s products include topical hemostat powder, hemostat dressing and intranasal splint, hemostat patch, topical hemostat sponge, intranasal splint, foam hemostat pad, and OTC powder and foam. Its hemostat dressing and intranasal splint is a foam splint made from natural chitosan based polymers; and hemostatic patch accelerates the clotting process to control bleeding. Hemostasis’ OTC powder and foam provides quick and painless solution from minor to moderate bleeding wounds. The company offers its products across the US. Hemostasis is headquartered in Saint Paul, Minnesota, the US. Key subsidiaries of Hemostasis include FIAGON AG Medical Technologies.
The key metrics of Hemostasis related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Hemostasis is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Hemostasis.
For a detailed understanding of the performance of Hemostasis, buy the report here.